Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer

ArticleinJournal of the National Cancer Institute 104(17):1335-42 · July 2012with17 Reads
Impact Factor: 12.58 · DOI: 10.1093/jnci/djs299 · Source: PubMed

Background: A growing proportion of men diagnosed with localized prostate cancer detected through prostate-specific antigen testing are dying from causes other than prostate cancer. Temporal trends in specific causes of death among prostate cancer patients have not been well described. Methods: We analyzed causes of death among all incident prostate cancer cases recorded in the nationwide Swedish Cancer Registry (1961-2008; n = 210 112) and in the US Surveillance, Epidemiology, and End Results Program (1973-2008; n = 490 341). We calculated the cumulative incidence of death due to seven selected causes that accounted for more than 80% of the reported deaths (including ischemic heart disease and non-prostate cancer) and analyzed mortality trends by calendar year and age at diagnosis and length of follow-up. Results: During follow-up through 2008, prostate cancer accounted for 52% of all reported deaths in Sweden and 30% of reported deaths in the United States among men with prostate cancer; however, only 35% of Swedish men and 16% of US men diagnosed with prostate cancer died from this disease. In both populations, the cumulative incidence of prostate cancer-specific death declined during follow-up, while the cumulative incidences of death from ischemic heart disease and non-prostate cancer remained constant. The 5-year cumulative incidence of death from prostate cancer among all men was 29% in Sweden and 11% in the United States. Conclusions: In Sweden and the United States, men diagnosed with prostate cancer are less likely to die from prostate cancer than from another cause. Because many of these other causes of death are preventable through changes in lifestyle, interventions that target lifestyle factors should be integrated into prostate cancer management.

Full-text preview

Available from: jnci.oxfordjournals.org
    • "Compared with female cancer survivors, male cancer survivors are approximately 30% more likely to meet the American Cancer Society's recommendations of >150 minutes of moderate-to-vigorous physical activity per week (Lemasters et al., 2014). Additionally, while data on the benefits of exercise specific to prostate cancer are not conclusive (Young-McCaughan, 2012), men with prostate cancer are more likely to die of cardiovascular disease than the prostate cancer itself (Epstein et al., 2012). Therefore, it is appropriate to include exercise in any lifestyle intervention designed to motivate men and improve prostate cancer-related outcomes. "
    [Show abstract] [Hide abstract] ABSTRACT: Obese men have a higher rate of prostate cancer-related death than non-obese men, and obesity increases the risk of prostate cancer progression and biochemical recurrence. The purpose of this study was to assess needs and interests of men for a technology-driven weight loss intervention to reduce prostate cancer risk. We distributed a survey collecting demographic characteristics, health history, exercise and eating habits (and perception of those habits), current and prior attempts of health behavior change, and technology use. Survey answers were summarized by count and percent of total respondents. Completed surveys (N = 109) described men with a family history of prostate cancer (25%), a history of elevated prostate specific antigen (26%), and prostate cancer survivors (22%). We compared body mass index (BMI) to perception of weight; overweight and obese men perceived their weight as more normal than their BMI category suggests. Most men reported their diet needed minor improvement (74%), and 65% of men reported they are either currently trying to lose weight or interested in weight loss. Most respondents access the internet (92%), while text messaging (60%) and smartphone application use (40%) are less frequent, especially in men over 60. Our results revealed a need and willingness for lifestyle modification and suggest a need for evidence-based weight loss strategies and for addressing the misperception of weight status. A male-tailored intervention that implements technology could improve energy balance, hold men accountable to healthy behavior change, and promote dietary patterns in order to reduce prostate cancer risk.
    Preview · Article · Mar 2016
    • "Men who were the most recreationally active before and after diagnosis experienced the lowest risk of all-cause mortality (and PCa mortality, although not statistically significant). The inverse association between total activity and allcause mortality may have been influenced by cardiovascular deaths, which were prevalent in our study and others [17,18] and are preventable with exercise [19]. We also showed that men maintaining high recreational activity levels pre-and postdiagnosis experienced the lowest allcause mortality rates. "
    [Show abstract] [Hide abstract] ABSTRACT: Despite the high global prevalence of prostate cancer (PCa), few epidemiologic studies have assessed physical activity in relation to PCa survival.
    Full-text · Article · Jan 2016 · European Urology
    • "This study demonstrated a crude one-year survival rate of 95% with variations related to age, which is similar to estimates from French cancer registries (92% one-year overall survival, and a specific survival rate of 96%) [15]. Causes of death other than PCa were reported for 80% of deceased patients in the United States and 65% of deceased patients in Sweden [16]. Patients with PCa, especially with metastatic disease, presented a higher risk of death by suicide or cardiovascular disease than the general population [17]. "
    [Show abstract] [Hide abstract] ABSTRACT: Background This very large population-based study investigated outcomes after a diagnosis of prostate cancer (PCa) in terms of mortality rates, treatments and adverse effects. Methods Among the 11 million men aged 40 years and over covered by the general national health insurance scheme, those with newly managed PCa in 2009 were followed for two years based on data from the national health insurance information system (SNIIRAM). Patients were identified using hospitalisation diagnoses and specific refunds related to PCa and PCa treatments. Adverse effects of PCa treatments were identified by using hospital diagnoses, specific procedures and drug refunds. Results The age-standardised two-year all-cause mortality rate among the 43,460 men included in the study was 8.4%, twice that of all men aged 40 years and over. Among the 36,734 two-year survivors, 38% had undergone prostatectomy, 36% had been treated by hormone therapy, 29% by radiotherapy, 3% by brachytherapy and 20% were not treated. The frequency of treatment-related adverse effects varied according to age and type of treatment. Among men between 50 and 69 years of age treated by prostatectomy alone, 61% were treated for erectile dysfunction and 24% were treated for urinary disorders. The frequency of treatment for these disorders decreased during the second year compared to the first year (erectile dysfunction: 41% vs 53%, urinary disorders: 9% vs 20%). The frequencies of these treatments among men treated by external beam radiotherapy alone were 7% and 14%, respectively. Among men between 50 and 69 years with treated PCa, 46% received treatments for erectile dysfunction and 22% for urinary disorders. For controls without PCa but treated surgically for benign prostatic hyperplasia, these frequencies were 1.5% and 6.0%, respectively. Conclusions We report high survival rates two years after a diagnosis of PCa, but a high frequency of PCa treatment-related adverse effects. These frequencies remain underestimated, as they are based on treatments for erectile dysfunction and urinary disorders and do not reflect all functional outcomes. These results should help urologists and general practitioners to inform their patients about outcomes at the time of screening and diagnosis, and especially about potential treatment-related adverse effects.
    Full-text · Article · Jun 2014 · BMC Urology
Show more